唑来膦酸对新疆哈萨克族老年男性骨质疏松患者的疗效观察  

Effect of zoledronic acid on osteoporosis in Xinjiang Kazak elderly male patients

作　　者：陆琳松[1] 孙俊刚[1] 钟惠琴[1] 孙治国[1] 周文正[1] 殷剑[1] 肖伟[1] 王浩[1] 袁宏[1] 

机构地区：[1]新疆维吾尔自治区人民医院骨外1科,乌鲁木齐830001

出　　处：《中国药物与临床》2015年第11期1554-1556,共3页Chinese Remedies & Clinics

基　　金：民政部"十一五"课题的子课题[民人教科字(2007)18-1-39]

摘　　要：目的探讨注射用唑来膦酸5 mg对新疆哈萨克族老年男性骨质疏松患者的临床疗效。方法选取2011年6月至2013年11月住院期间哈萨克族老年男性骨质疏松患者62例,所有患者均初次诊断为骨质疏松症,未曾行任何抗骨质疏松治疗,同时排除其他骨代谢性疾病或药物影响,随机分为治疗组(32例),给予唑来膦酸5 mg,静脉滴注30 min,同时口服碳酸钙D3(钙尔奇)600 mg/d及1α-羟基维生素D3 0.25μg/d;对照组(30例),给予口服碳酸钙D3600 mg/d及1α-羟基维生素D3 0.25μg/d,治疗时间1年,采用双能X线骨密度仪(DEXA)测定2组治疗前后的腰椎1-4、股骨颈、Ward三角区骨密度值。结果排除治疗组中2例患者脱失外,治疗组骨密度增幅程度均显著高于对照组(P<0.05)。6例患者在注射唑来膦酸后出现发热、头痛及流感样症状,给予非甾体抗炎药(NSAIDs)对症治疗后6例患者均在3 d内缓解,未见其他不良反应。结论唑来膦酸注射液5mg可明显提高新疆哈萨克族老年男性骨质疏松患者的骨密度,抑制骨量丢失,降低骨折风险,提高患者依从性,不良反应可耐受,是治疗新疆哈萨克族老年男性骨质疏松患者的高效药物。Objective To investigate the clinical effect of 5 mg zoledronic acid for injection on osteoporosis in Xinjiang Kazak elderly male patients.Methods Sixty-two Kazak elderly male patients with osteoporosis hospitalized between June 2011 and November 2013 were included in the study.All patients were first diagnosed with osteoporo-sis,never received any anti-osteoporosis treatment,while excluding other bone metabolic diseases or the influence of drugs.All patients were randomly divided into the treatment group（n=32） and the control group（n=30）.The treatment group was given 5 mg zoledronic acid,30 min intravenous infusion,and 600 mg/d oral caltrate and 0.25 μg/d alpha D3,and the control group was given 600 mg/d oral caltrate and 0.25 μg/d alpha D3 for one-year treatment.The dualenergy X-ray absorptiometry（DEXA） was used to measure the bone mineral density（BMD） of lumbar spine 1-4,femoral neck,and Ward′s triangle region before and after the treatment.Results Excluding 2 patients dropped out in the treatment group,the increasing degree of BMD in the treatment group was significantly higher than that in the control group（P0.05）.Fever,headache and flu-like symptoms were found in six patients after the injection of Zoledronic Acid.All 6 patients were relieved in 3 days after given symptomatic treatment of NSAIDs,without other ad-verse reactions.Conclusion Five mg zoledronic acid injection can significantly improve the BDM in Xinjiang Kazak elderly male patients with osteoporosis,inhibit bone loss,reduce fracture risk and improve patient compliance and ad-verse reaction tolerance,which is the highly-effective drug for the treatment of osteoporosis in Xinjiang Kazak elderly male patients.

关 键 词：骨质疏松 唑来膦酸 骨密度 老年男性 哈萨克族 

分 类 号：R580[医药卫生—内分泌]